Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 35Neoplasm Metastasis 32Myelodysplastic Syndromes 18Lung Neoplasms 16Colorectal Neoplasms 14Pancreatic Neoplasms 12Breast Neoplasms 12Multiple Myeloma 11Leukemia, Lymphocytic, Chronic, B-Cell 11Carcinoma, Non-Small-Cell Lung 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Melanoma 10Triple Negative Breast Neoplasms 9Prostatic Neoplasms 9Glioblastoma 9Lymphoma, Follicular 8Carcinoma, Renal Cell 8Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell 7Astrocytoma 7Ovarian Neoplasms 6Glioma 6Burkitt Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Lymphoma, T-Cell 5Lymphoma, Mantle-Cell 5Leukemia, Biphenotypic, Acute 5Hematologic Neoplasms 5Stomach Neoplasms 4

Interventions

Dexamethasone 2silmitasertib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1filanesib 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1Steroids 1Specimen Handling 1Sodium Selenite 1Radiotherapy 1Radiation 1Proteasome Inhibitors 1Lenalidomide 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Calcium Dobesilate 1Bortezomib 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Plasmacytoma × Specimen Handling × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡